|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction显示文摘 | | 2001 | Lancet2001，358，9282： | 1 |
| 2 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractioned heparin the ASSENT-3 randomized,trial in acute myocardial infarction显示文摘 | THE ASSESSMENT OF THE SAFETY AND EFFICACY OF ANEW THROMBOLYTIC REGIMEN (ASSENT-3) INVESTIGATORS | 2001 | Lancet2001，358，： | 1 |
| 3 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractionated heparin:the ASSENT-3 randomised trial in acute myocardial infarction显示文摘 | Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators | | 0，，： | 1 |
| 4 | Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractiionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction 显示文摘 | Assessment of the Safety and Efficacy of a New Thrombolytic Regimen ( ASSENT)-3 Investigators | 2001 | Lancet2001，358，9282： | 1 |
| 5 | The Postmenopausal Estrogen/Progestin Interventions(PEPI)Trial显示文摘 | Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women | 1995 | JAMA1995，273，： | 1 |
| 6 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractioned heparin the ASSENT-3 raodomized,trial in acute myocardial infarction显示文摘 | The assessment of the stfety and efficacy of a new thrombolyiic regimen (ASSENT-3) investigators | 2001 | Lancet2001，358，： | 1 |
| 7 | The results up to 30 months显示文摘 | Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong | 1977 | Am Rev Respir Dis1977，115，5： | 1 |
| 8 | metastatic coloreetal carcinoma显示文摘 | Pasquale C Antonio G Antonio F et aL A tailored regimen including capecitabine and oxaliplatin for treating el- derly patients with | 2005 | Critical Reviews in Oncology/Hematology2005，53，2： | 1 |
| 9 | Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthet?ic heart valves on longterm oral anticoagulants (from the REGI?MEN Registry)显示文摘 | Spyropoulos AC Turpie AG Dunn AS REGIMEN Investiga?tors | 2008 | Am J Cardiol2008，102，7： | 1 |
| 10 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractioned heparin the ASSENT-3 randomized,trial in acute myocardial infarction显示文摘 | The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3 Investigators | 2001 | Lancet2001，358，： | 1 |
| 11 | Efficacy and safety of tenecteplase in combination with enoxaparin, abeiximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction显示文摘 | Assessment of the Safety and Efficacy of a New Thrombolytic Regimen ( ASSENT) -3 Investigators | 2001 | Lancet2001，358，： | 1 |
| 12 | Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin:the ASSENT -3 randomised trial in acute myocardial infarction 显示文摘 | Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)- 3 Investigators | 2001 | Lancet2001，358，： | 1 |
| 13 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractioned heparin the ASSENT-3 randomized,trial in acute myocardial infarction显示文摘 | | 2001 | Lancet2001，358，： | 1 |
| 14 | Efficacy and safety of tenecteplase in combination with enoxaparin abciximab or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction显示文摘 | Assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT-3) investigators | 2001 | Lancet2001，358，9282： | 1 |
| 15 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab, or unfractionated heparin: The ASSENT-3 randomized trial in acute myocardial infarction显示文摘 | The Assessment of the Safery and Efficacy of a New Thrombolytic Regimen(ASSENT)-3 Investigators | 2001 | Lancet2001，358，9282： | 1 |
| 16 | Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin:the ASSENT-3 randomised trial in acute myocardial infarction显示文摘 | Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators | 2001 | Lancet2001，358，9282： | 1 |
| 17 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractioned heparin the ASSENT-3 randomized, trial in acute myocardial infarction显示文摘 | The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators | 2001 | Lancet2001，358，： | 1 |
| 18 | A randomized,controlled trial 显示文摘 | Yki - Jarvinen H Ryysy L Nikkila K time insulin regimens in patients with type 2 diabetes mellitus | 1999 | Ann Int Med1999，130，： | 1 |
| 19 | Efficacy and safety of tenecteplase in combination with enoxaparin,abciximab,or unfractionated heparin:theASSENT-3 randomized trial in acute myocardial infarction显示文摘 | | 2001 | Lancet2001，358，9282： | 1 |
| 20 | Efficacy and safety of tenecteplade in combination with enoxaparin,abciximeb,or unfractionated heparin:the ASSENT-3 randomised trial in acute myocardial infarction显示文摘 | The Assessment of the safety and efficacy of a new thrombolytic regimen(ASSENT-3)investigators | 2001 | Lancet2001，358，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员